This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
Few medical questions have aroused vigorous debate to the extent of that generated by the degree of use of anticoagulants in coronary heart disease. Medical News has asked four cardiologists—each with different views—to participate in a symposium, in which each has answered four questions:
•Should anticoagulants be used at all in acute myocardial infarction? If yes, in good risk or bad risk patients?
•What is the status of anticoagulants in long-term therapy? How long should they be continued after infarction?
•What is their status in impending infarction (angina pectoris)?
•What is the level of prothrombin time? Is its action predominantly at the heart or the peripheral vessels?
Answering these questions are the following cardiologists:
William B. Likoff, MD, clinical professor of medicine and head of the cardiovascular section at Hahnemann Medical College and Hospital in Philadelphia.
L. E. Meltzer, MD, codirector of the section of clinical investigation at The Presbyterian
MEDICAL NEWS. JAMA. 1963;184(11):29-48. doi:10.1001/jama.1963.03700240003002